AI Article Synopsis
- - The study aimed to examine how carvedilol impacts neurohormone levels and magnesium metabolism in patients with chronic heart failure (CHF) over an 8-week period.
- - Fifty-seven CHF patients were split into two groups: one receiving standard treatment and the other receiving carvedilol alongside standard treatment, with key measurements taken before and after.
- - Results showed that carvedilol significantly lowered levels of neurohormones and urine magnesium excretion while enhancing cell magnesium content in CHF patients compared to controls.
Article Abstract
Objective: To investigate the effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure (CHF).
Methods: Fifty-seven patients with CHF were divided into two groups randomly: received conventional treatment alone or combined with carvedilol for 8 weeks, respectively. Urine magnesium excretion (UME), plasma levels of magnesium (PMC), norepinephrine (NE), angiotensin-II (Ang-II), aldosterone (ALD), plasma renin activity (PRA) and peripheral monocyte magnesium content (MMC) were measured before and after treatments. Twenty-six health persons were selected as normal subjects.
Results: There was a significant increase in UME and plasma concentrations of NE, ALD, Ang-II and PRA, and a significant decrease in MMC in patients with CHF, compared with the control group (P < 0.01). UME was positively correlated with ALD, Ang-II, PRA r = 0.41, 0.42, 0.38, respectively (P < 0.01). These parameters significantly improved after carvedilol (P < 0.05).
Conclusion: Carvedilol decreases significantly plasma concentrations of neurohormone and urine magnesium excretion, and increases cell magnesium content in patients with CHF.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!